What’s Ahead for Concordia Healthcare Corp After Today’s Huge Increase?
The stock of Concordia Healthcare Corp (TSE:CXR) is a huge mover today! The stock is up 12.88% or $3.81 after the news, hitting $33.4 per share. About 1.05 million shares traded hands or 21.80% up from the average. Concordia Healthcare Corp (TSE:CXR) has declined 42.09% since October 7, 2015 and is downtrending. It has underperformed by 45.52% the S&P500. The move comes after 8 months positive chart setup for the $1.67 billion company. It was reported on May, 13 by Barchart.com. We have $49.43 PT which if reached, will make TSE:CXR worth $801.60 million more.
Out of 11 analysts covering Concordia Healthcare Corp (TSE:CXR), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. $77.72 is the highest target while $26 is the lowest. The $44.89 average target is 173.20% above today’s ($33.4) stock price. Concordia Healthcare Corp has been the topic of 9 analyst reports since August 11, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the stock on January 8 with “Outperform” rating.
Concordia Healthcare Corp. is a Canada diverse healthcare company. The company has a market cap of $1.67 billion. The Firm is focused on legacy pharmaceutical products and orphan drugs. It currently has negative earnings. The Firm operates through three divisions, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc., which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran , for treatment of partial seizures in adults with epilepsy.
https://www.franklinindependent.com/whats-ahead-for-concordia-healthcare-corp-after-todays-huge-increase-3/